Literature DB >> 2072121

Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.

M Kuriyama1, J Fujiyama, H Yoshidome, S Takenaga, K Matsumuro, T Kasama, K Fukuda, T Kuramoto, T Hoshita, Y Seyama.   

Abstract

We present the clinical and laboratory findings of 8 patients with cerebrotendinous xanthomatosis. The clinical features consisted of a combination of bilateral Achilles tendon xanthomas, cataracts, low intelligence, pyramidal signs, cerebellar signs, convulsions, peripheral neuropathy, foot deformity, cardiovascular disease or atherosclerosis, EEG abnormality, and increased CSF protein. Increased cholesterol was present in the serum, CSF and red cell membrane of all 8 patients. The bile of one patient with late age onset of the disease showed an attenuated production of bile acids and bile alcohols. Three of the 7 had obstruction and/or marked narrowing of the coronary arteries. Data on 136 patients reported throughout the world are reviewed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072121     DOI: 10.1016/0022-510x(91)90073-g

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  21 in total

1.  Paediatric cerebrotendinous xanthomatosis.

Authors:  R A Wevers; J R Cruysberg; A F Van Heijst; F S Janssen-Zijlstra; W O Renier; B G Van Engelen; J J Tolboom
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis.

Authors:  J R M Cruysberg
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

3.  A useful multi-analyte blood test for cerebrotendinous xanthomatosis.

Authors:  Andrea E DeBarber; Jenny Luo; Roberto Giugliani; Carolina F M Souza; John Pei-Wen Chiang; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Clin Biochem       Date:  2014-04-21       Impact factor: 3.281

4.  Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion.

Authors:  Ryuta Abe; Yoshiki Sekijima; Tomomi Kinoshita; Tsuneaki Yoshinaga; Shingo Koyama; Takeo Kato; Shu-Ichi Ikeda
Journal:  J Spinal Cord Med       Date:  2016-02-25       Impact factor: 1.985

5.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

6.  Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism.

Authors:  N Wakamatsu; M Hayashi; H Kawai; H Kondo; Y Gotoda; Y Nishida; R Kondo; S Tsuji; T Matsumoto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

7.  Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients.

Authors:  Y Hokezu; M Kuriyama; R Kubota; M Nakagawa; J Fujiyama; M Osame
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

8.  Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics.

Authors:  E Leitersdorf; R Safadi; V Meiner; A Reshef; I Björkhem; Y Friedlander; S Morkos; V M Berginer
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

Review 9.  Mechanisms of disease: Inborn errors of bile acid synthesis.

Authors:  Shikha S Sundaram; Kevin E Bove; Mark A Lovell; Ronald J Sokol
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-06-24

10.  Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy.

Authors:  Germaine Pierre; Kenneth Setchell; Jacqueline Blyth; Mary Anne Preece; Anupam Chakrapani; Patrick McKiernan
Journal:  J Inherit Metab Dis       Date:  2008-12-27       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.